MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
MacroGenics (MGNX) reported that it announced financial and operating results for the quarter ended September 30, 2025. The company furnished a detailed press release as Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, is provided as “furnished” under the Exchange Act and is not deemed “filed.”
MacroGenics, Inc. reported Q3 results showing total revenue of $72.8 million versus $110.7 million a year ago, reflecting lower milestone revenue, partly offset by stronger contract manufacturing. Contract manufacturing revenue rose to $19.8 million from $4.6 million. Research and development expense declined to $32.7 million from $40.5 million.
The company generated quarterly net income of $16.8 million (basic and diluted EPS $0.27), compared with $56.3 million last year. Year to date, it recorded a net loss of $60.5 million as operating cash outflows reached $124.1 million. Cash and cash equivalents were $80.1 million with marketable securities of $66.3 million. Stockholders’ equity was $67.0 million.
In June, MacroGenics sold future ZYNYZ royalties to Sagard for $70.0 million, recognizing a liability of $70.3 million with an estimated effective interest rate of 18.6% and booked $3.3 million non-cash interest in Q3. It also recognized $50.0 million from two Sanofi regulatory milestones, included in accounts receivable at quarter end. Subsequent to quarter end, Gilead nominated a second research program and exercised its option, obligating a total of $25.0 million. Shares outstanding were 63,258,532 as of November 7, 2025. Management cites a cash runway into late 2027.
William K. Heiden, a director of MacroGenics, Inc. (MGNX), reported two open-market purchases of the company's common stock. On 08/19/2025 he purchased 50,500 shares at aggregate prices reported as $1.52 with trade prices in a range of $1.48 to $1.59, bringing his direct beneficial ownership to 61,500 shares. On 08/20/2025 he purchased an additional 49,500 shares at an aggregate price reported as $1.49 with trade prices in a range of $1.46 to $1.50, increasing his direct beneficial ownership to 111,000 shares. The Form 4 was signed by attorney-in-fact Beth A. Smith on 08/21/2025.
Thomas Spitznagel, Sr. VP Technical Ops at MacroGenics, Inc. (MGNX), acquired 30,000 shares of common stock through the exercise of employee stock options on 08/15/2025. The options had an exercise price of $1.58 and convert to 30,000 shares upon exercise. After the reported transaction, 30,000 shares are beneficially owned directly. The option grant vests 25% one year after the grant date with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
MacroGenics insider award: Senior Vice President and General Counsel Jeffrey Stuart Peters received an employee stock option grant for 30,000 shares on 08/15/2025. The option has an exercise price of $1.58, vests 25% after one year with the remaining 75% vesting in 12 substantially equal quarterly installments, and expires on 08/15/2035. Following the reported transaction Mr. Peters beneficially owns 30,000 common shares subject to the option on a direct basis. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
MACROGENICS INC director Scott Koenig reported the vesting and conversion of restricted stock units (RSUs) into common shares. On 2025-08-13, a total of 52,829 RSUs (21,165 and 31,664 units) were exercised or converted into 52,829 shares of common stock at a stated price of $0.00 per share.
According to a Separation and Consulting Agreement between the company and Koenig, 50% of each outstanding and unvested RSU immediately vested, and the vested shares are to be delivered to him as soon as practicable after the vesting date. Each RSU represents a contingent right to receive one common share.
Insider option grant to CEO/Director MacroGenics reported that Eric Blasius Risser, who serves as President and CEO and a director, was granted an employee stock option covering 550,000 shares of common stock with an exercise price of $1.66. The option was granted with an exercise schedule that vests 25% one year after grant and the remaining 75% in 12 substantially equal quarterly installments thereafter. The options are exercisable through 08/13/2035 and are directly owned by the reporting person following the transaction.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.
MacroGenics, Inc. filed a current report to furnish its financial and operating results for the quarter ended June 30, 2025. The company announced these quarterly results on August 14, 2025 and provided the full details in a press release attached as Exhibit 99.1.
The company states that the information in this report, including the press release, is being furnished rather than filed under securities laws. This means it is not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
The Frazier Life Sciences reporting group disclosed specific holdings in MacroGenics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 1,549,193 shares representing 2.5% of the 63,090,323 shares outstanding used for the percentage calculation. Other reporting entities hold 925,809 shares (1.5%), 575,150 shares (0.9%) and 125,513 shares (0.2%).
The filing states that voting and dispositive power for these shares is shared rather than sole and corrects prior attributions by clarifying that members of certain investment committees are not attributed beneficial ownership of the securities held by the respective funds. The statement also notes the reporters do not admit broader beneficial ownership or group status beyond what is disclosed.